At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 834 enrolled
Drug / intervention
Atogepant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
In Brief
A Phase 3 clinical trial evaluating Atogepant and Placebo-matching Atogepant for Migraine, With or Without Aura. Completed, enrolled 834 participants across 75 sites.
Detailed Summary
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartSep 2016
Primary CompletionApr 2018
Study CompletionApr 2018
TodayJul 2026
First PostedJul 28, 2016
Enrollment StartSep 6, 2016
Primary CompletionApr 2, 2018
Study CompletionApr 23, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.9 years ago
Interventions
Atogepantdrug
Atogepant capsule.
Placebo-matching Atogepantdrug
Placebo-matching atogepant capsule.